Director/PDMR Shareholding
Summary by AI BETAClose X
Haleon plc: Director/PDMR Shareholding
13 March 2026: Haleon plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today announces notification and public disclosure in accordance with the requirements of The UK Market Abuse Regulation of Transactions by Persons Discharging Managerial Responsibilities ("PDMRs").
This notification sets out the details of the grant of Haleon share awards over Ordinary Shares made to PDMRs under the Haleon Performance Share Plan and Deferred Annual Bonus Plan.
The Performance Share Plan main awards are subject to performance conditions over the performance period ending on 31 December 2028. Performance targets are disclosed in the 2025 Annual Report and 20-F.
All awards were made in line with the principles of Haleon's Directors' Remuneration Policy and are subject to malus and clawback provisions.
|
1
|
Details of the issuer or emission allowance market participant
|
|||||
|
a)
|
Name of the entity
|
Haleon plc |
||||
|
b)
|
LEI
|
549300PSB3WWEODCUP19 |
||||
|
2
|
Reason for the notification
|
|||||
|
a)
|
Position/status
|
Chief Executive Officer |
||||
|
b)
|
Initial notification /Amendment to prior notifications
|
Initial Notification |
||||
|
3
|
Details of the person discharging managerial responsibilities / person closely associated ("PCA") |
|||||
|
a) |
PDMR/PCA |
PDMR
|
||||
|
b)
|
Name
|
Brian McNamara |
||||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
|||||
|
a)
|
Description of Instrument |
Share
|
||||
|
|
|
|||||
|
Identification code |
GB00BMX86B70
|
|||||
|
|
|
|||||
|
b)
|
Nature of the transaction
|
(i) Grant of a conditional award under the Haleon plc Performance Share Plan (ii) Grant of a conditional award under the Haleon plc Deferred Annual Bonus Plan |
||||
|
c)
|
Currency, Price(s) and Volume(s) |
|
|
|
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
|
(i) |
Nil |
1,639,855 |
|
|
|
|
|
(ii) |
Nil |
173,825 |
|
|
|
|
|
|
|
|
||
|
d)
|
Aggregated information |
|
||||
|
|
|
|||||
|
- Aggregated volume |
1,813,680 |
|||||
|
|
|
|||||
|
- Price |
Nil |
|||||
|
|
|
|||||
|
e)
|
Date of the transaction
|
12 March 2026 |
||||
|
f)
|
Place of the transaction
|
Outside a trading venue
|
||||
|
1
|
Details of the issuer or emission allowance market participant
|
|||||
|
a)
|
Name of the entity
|
Haleon plc |
||||
|
b)
|
LEI
|
549300PSB3WWEODCUP19 |
||||
|
2
|
Reason for the notification
|
|||||
|
a)
|
Position/status
|
Chief Financial Officer |
||||
|
b)
|
Initial notification /Amendment to prior notifications
|
Initial Notification |
||||
|
3
|
Details of the person discharging managerial responsibilities / person closely associated ("PCA") |
|||||
|
a) |
PDMR/PCA |
PDMR
|
||||
|
b)
|
Name
|
Dawn Allen |
||||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
|||||
|
a)
|
Description of Instrument |
Share
|
||||
|
|
|
|||||
|
Identification code |
GB00BMX86B70
|
|||||
|
|
|
|||||
|
b)
|
Nature of the transaction
|
(i) Grant of a conditional award under the Haleon plc Performance Share Plan (ii) Grant of a conditional award under the Haleon plc Deferred Annual Bonus Plan |
||||
|
c)
|
Currency, Price(s) and Volume(s) |
|
|
|
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
|
(i) |
Nil |
712,784 |
|
|
|
|
|
(ii) |
Nil |
95,513 |
|
|
|
|
|
|
|
|
||
|
d)
|
Aggregated information |
|
||||
|
|
|
|||||
|
- Aggregated volume |
808,297 |
|||||
|
|
|
|||||
|
- Price |
Nil |
|||||
|
|
|
|||||
|
e)
|
Date of the transaction
|
12 March 2026 |
||||
|
f)
|
Place of the transaction
|
Outside a trading venue
|
||||
Amanda Mellor
Company Secretary
About Haleon
Haleon (LSE/NYSE: HLN) is a consumer company that is solely focused on better everyday health. Our people, our brands, our research, our investment and our innovation are aimed at improving the everyday health of consumers. Our product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Our superior brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are trusted by more than one billion consumers and are recommended by health professionals around the world.
For more information, please visit www.haleon.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 2 hours ago Savannah Energy
- 3 hours ago Buccaneer Energy PLC
- 4 hours ago Savannah Energy
- 4 hours ago Carclo
- 4 hours ago Schroder Japan Growth Fund